ibandronic acid has been researched along with clodronic acid in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (15.09) | 18.2507 |
| 2000's | 24 (45.28) | 29.6817 |
| 2010's | 18 (33.96) | 24.3611 |
| 2020's | 3 (5.66) | 2.80 |
| Authors | Studies |
|---|---|
| Almeida Paz, FA; Barbosa, JS; Braga, SS | 1 |
| Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K | 1 |
| Collin, P; Fleisch, H; Guenther, HL; Martin, TJ; Sahni, M | 1 |
| Antic, VN; Fleisch, H; Mühlbauer, RC | 1 |
| Burckhardt, P; Fioroni, P; Juillerat, L; Leuenberger, P; Ludwig, H; Markert, M; Pecherstorfer, M; Sauty, A; Thiebaud, D; Zimmer-Roth, I | 1 |
| Boissier, S; Clezardin, P; Cuzin, B; Delmas, PD; Ebetino, FH; Frappart, L; Magnetto, S | 1 |
| Coxon, FP; Graham, R; Hughes, DE; Luckman, SP; Rogers, MJ; Russell, G | 1 |
| Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD | 1 |
| Cohen, L; Löwik, C; Papapoulos, S; Pieterman, E; van Beek, E | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Horn, E; Jilch, R; Keck, AV; Pecherstorfer, M; Sauty, A; Thiebaud, D; Zimmer-Roth, I | 1 |
| Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
| Body, JJ | 1 |
| Body, JJ; Fromigue, O; Lagneaux, L | 1 |
| Body, JJ; Fromigué, O | 1 |
| Boissier, S; Cabon, F; Clézardin, P; Colombel, M; Filleur, S; Fournier, P; Guglielmi, J | 1 |
| Frith, JC; Rogers, MJ | 1 |
| Berenson, JR | 1 |
| Adami, S; Crepaldi, G; Filipponi, P; Sartori, L | 1 |
| Berenson, J; Hirschberg, R | 1 |
| Boos, J; Lanvers-Kaminsky, C; Vorotnjak, M | 1 |
| Khuri, F; Saba, N | 1 |
| Coleman, RE | 1 |
| Balla, J | 1 |
| Lugassy, G | 1 |
| Atzpodien, E; Bauss, F; Bohrmann, B; Pfister, T | 1 |
| Franke, HR; Verdijk, R; Vermes, I; Wolbers, F | 1 |
| Langdahl, B; Mosekilde, L; Vestergaard, P | 1 |
| Alva, D; Cesareo, R; Contini, S; De Rosa, B; Iozzino, M; Lauria, A; Mallardo, L; Napolitano, C; Orsini, A; Reda, G | 1 |
| Bauss, F; Haiker, M; Künkele, KP; Lühe, A; Pfister, T; Schad, K; Suter, L; Zihlmann, C | 1 |
| Márton, I; Redl, P; Udvardy, E | 1 |
| Bartl, R | 1 |
| Al-Nawas, B; Brüllmann, D; Gauss, L; Kämmerer, P; Klein, MO; Pabst, A; Walter, C; Ziebart, T | 1 |
| Al-Nawas, B; Klein, M; Pabst, A; Walter, C; Ziebart, T | 1 |
| Al-Nawas, B; Koch, FP; Merkel, C; Smeets, R; Walter, C; Ziebart, T | 1 |
| Bainton, R; Hindawi, M; Srinivasan, D | 1 |
| Bauss, F; Drosse, I; Ehrenfeld, M; Opelz, C; Otto, S; Pautke, C; Schieker, M; Schwager, J; Westphal, I | 1 |
| Al-Nawas, B; Koch, FP; Merkel, C; Smeets, R; Wagner, W; Walter, C; Ziebart, T | 1 |
| Al-Nawas, B; Koch, FP; Pabst, AM; Taylor, KY; Walter, C; Ziebart, T | 1 |
| Dinh, L; Kamara, H; Lee, J; Opperman, LA; Reuben, JS; Stateson, J; Xiang, L | 1 |
| Ben-Aharon, I; Rizel, S; Shpilberg, O; Stemmer, SM; Sulkes, A; Vidal, L; Yerushalmi, R | 1 |
| Brown, J; Fullarton, JR; Palmieri, C | 1 |
| Alegre, A; Bailén, A; Giraldo, P; Gironella, M | 1 |
| Hagelauer, N; Pabst, AM; Ulbrich, H; Walter, C; Ziebart, T | 1 |
| Criscitiello, C; Curigliano, G; De Laurentiis, M; De Placido, S; Esposito, A; Gelao, L; Goldhirsch, A; Santangelo, M; Viale, G | 1 |
| De Luna-Bertos, E; García-Martínez, O; Manzano-Moreno, FJ; Ramos-Torrecillas, J; Ruiz, C | 1 |
| Jacobs, C; Krüger, M; Pabst, AM; Sagheb, K; Walter, C; Ziebart, T | 1 |
| Mészaros, Á; Veszelyné Kotán, E | 2 |
| Al-Nawas, B; Jung, J; Kwon, YD; Pabst, AM; Park, JS; Righesso, L; Walter, C | 1 |
| Abrams, JS; Barlow, WE; Chew, HK; Clemons, M; Dakhil, SR; Dammann, KZ; Dees, EC; Elias, AD; Falkson, CI; Gralow, JR; Hayes, DF; Hershman, DL; Hortobagyi, GN; Ingle, JN; Lew, DL; Livingston, RB; M'iao, JL; Margolis, JH; Messino, MJ; Paterson, AHG; Schubert, MM; Stopeck, AT; Van Poznak, CH | 1 |
| Halling, F; Lux, C; Otto, M; Schlittenbauer, T; Ziebart, T | 1 |
17 review(s) available for ibandronic acid and clodronic acid
| Article | Year |
|---|---|
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans | 2021 |
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Multiple Myeloma; Pain; Pamidronate | 1998 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Current and future directions in medical therapy: hypercalcemia.
Topics: Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid | 2000 |
Treatment of hypercalcemia of malignancy with bisphosphonates.
Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid | 2002 |
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
Topics: Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Zoledronic Acid | 2003 |
Safety and convenience of a 15-minute infusion of zoledronic acid.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2004 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clodronic Acid; Diphosphonates; Etidronic Acid; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Imidazoles; Lung Neoplasms; Pamidronate; Positron-Emission Tomography; Predictive Value of Tests; Therapeutic Equivalency; Zoledronic Acid | 2005 |
Bisphosphonates in breast cancer.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Staging; Pamidronate; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2005 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Pamidronate; Parathyroid Hormone; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D | 2006 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Vitamin D | 2007 |
[Osteonecrosis of the jaw developing during bisphosphonate treatment].
Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Mandible; Mandibular Diseases; Oral Hygiene; Oral Surgical Procedures; Osteonecrosis; Patient Care Team; Referral and Consultation; Zoledronic Acid | 2008 |
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Female; Humans; Ibandronic Acid; Pamidronate; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Risedronic Acid; Risk; Treatment Outcome | 2013 |
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Neoplasm Metastasis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2013 |
Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.
Topics: Antineoplastic Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Ibandronic Acid; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2014 |
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Clodronic Acid; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Immune System; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Treatment Outcome; Zoledronic Acid | 2015 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
4 trial(s) available for ibandronic acid and clodronic acid
| Article | Year |
|---|---|
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.
Topics: Aged; Aged, 80 and over; Bone Resorption; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Interleukin-1; Interleukin-6; Male; Middle Aged; Neoplasms; Pamidronate; Tumor Necrosis Factor-alpha | 1996 |
Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Lectins, C-Type; Lymphocyte Subsets; Male; Middle Aged; Pamidronate; Prospective Studies; Tumor Necrosis Factor-alpha | 2000 |
S0307. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Predictive Value of Tests; Survival Rate; Zoledronic Acid | 2005 |
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
32 other study(ies) available for ibandronic acid and clodronic acid
| Article | Year |
|---|---|
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Ibandronic Acid; Injections, Intravenous; Osteoclasts; Pamidronate; Rats; Retinoids; Risedronic Acid; Spectrophotometry, Atomic; Tetracycline; Thyroxine | 1991 |
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.
Topics: Alendronate; Animals; Animals, Newborn; Bone Resorption; Cell Line; Cells, Cultured; Clodronic Acid; Culture Media, Conditioned; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Ibandronic Acid; Kinetics; Osteoblasts; Pamidronate; Parathyroid Hormone; Rats; Rats, Wistar; Time Factors | 1993 |
Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Calcium, Dietary; Clodronic Acid; Diphosphonates; Disease Models, Animal; Homeostasis; Ibandronic Acid; Male; Rats; Rats, Wistar; Tetracycline | 1996 |
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
Topics: Bone Matrix; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Cell Adhesion; Cell Adhesion Molecules; Clodronic Acid; Diphosphonates; Extracellular Matrix; Female; Humans; Ibandronic Acid; In Vitro Techniques; Integrins; Male; Neoplasm Metastasis; Osteoblasts; Pamidronate; Prostatic Neoplasms; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured | 1997 |
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Topics: Alendronate; Animals; Apoptosis; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Macrophages; Mevalonic Acid; Mice; Osteoclasts; Protein Prenylation; Protein Processing, Post-Translational; ras Proteins; Risedronic Acid; Structure-Activity Relationship | 1998 |
Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.
Topics: Animals; Bone Resorption; Brain; Carbon-Carbon Double Bond Isomerases; Cattle; Clodronic Acid; Dimethylallyltranstransferase; Diphosphonates; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Hemiterpenes; Ibandronic Acid; Mice; Multienzyme Complexes; Nitrogen; Pamidronate | 1999 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |
Bisphosphonates induce breast cancer cell death in vitro.
Topics: Amino Acid Chloromethyl Ketones; Annexins; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase Inhibitors; Caspases; Cell Death; Cell Nucleus; Clodronic Acid; Cysteine Proteinase Inhibitors; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Ibandronic Acid; Imidazoles; Kinetics; Pamidronate; Tumor Cells, Cultured; Zoledronic Acid | 2000 |
Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts.
Topics: Adult; Aged; Alkaline Phosphatase; Cell Differentiation; Cell Division; Cell Survival; Cells, Cultured; Clodronic Acid; Collagen Type I; Culture Media; Culture Media, Serum-Free; Diphosphonates; Fetal Blood; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoblasts; Pamidronate; Zoledronic Acid | 2002 |
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
Topics: Angiogenesis Inhibitors; Animals; Bone and Bones; Cell Division; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelium, Vascular; Epithelial Cells; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Neovascularization, Physiologic; Orchiectomy; Osteitis Deformans; Prostate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Testosterone; Tissue Distribution; Zoledronic Acid | 2002 |
Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Topics: Adenosine Triphosphate; Alendronate; Animals; Apoptosis; Blotting, Western; Bone Resorption; Cell Line; Cell Membrane; Cell Nucleus; Cells, Cultured; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Ibandronic Acid; Macrophages; Mice; Microscopy, Fluorescence; Osteoclasts; Pinocytosis; Rabbits; Time Factors | 2003 |
In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Topics: Alendronate; Apoptosis; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Diphosphonates; Drug Screening Assays, Antitumor; Germany; Humans; Ibandronic Acid; Imidazoles; Neuroblastoma; Pamidronate; Time Factors; Zoledronic Acid | 2004 |
The issue of renal safety of zoledronic acid from a nephrologist's point of view.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2005 |
"Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2005 |
Acute renal effects of intravenous bisphosphonates in the rat.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Female; Ibandronic Acid; Imidazoles; Injections, Intravenous; Kidney; Rats; Rats, Inbred Strains; Zoledronic Acid | 2005 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid | 2007 |
Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety.
Topics: Animals; Bone Density Conservation Agents; Cell Line; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Geranyltranstransferase; Humans; Ibandronic Acid; Imidazoles; Inhibitory Concentration 50; Kidney; Male; Pamidronate; Rats; Rats, Sprague-Dawley; RNA, Messenger; Zoledronic Acid | 2008 |
[Bisphosphonates for osseus invasion caused by bronchial carcinoma].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bronchial Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Osteoporosis; Zoledronic Acid | 2008 |
Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro.
Topics: Analysis of Variance; Apoptosis; Bone Density Conservation Agents; Cell Movement; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelial Cells; Endothelium, Vascular; Humans; Ibandronic Acid; Imidazoles; Leukocytes, Mononuclear; Neovascularization, Physiologic; Pamidronate; Statistics, Nonparametric; Stem Cells; Umbilical Veins; Zoledronic Acid | 2011 |
Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.
Topics: Apoptosis; Bone Density Conservation Agents; Cell Culture Techniques; Cell Movement; Cell Survival; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelial Cells; Endothelium, Vascular; Fibroblasts; Fluoresceins; Fluorescent Dyes; Humans; Ibandronic Acid; Imidazoles; In Situ Nick-End Labeling; Nitrogen; Osteoblasts; Pamidronate; Umbilical Veins; Zoledronic Acid | 2011 |
Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro.
Topics: Bone Density Conservation Agents; Cell Culture Techniques; Cell Line; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Ibandronic Acid; Imidazoles; Osteoblasts; Osteoprotegerin; RANK Ligand; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Zoledronic Acid | 2012 |
Non-surgical management of stage 3 biphosphonate-related oroantral fistula.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Conservation Agents; Clindamycin; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Hydrogen Peroxide; Ibandronic Acid; Maxillary Diseases; Middle Aged; Oroantral Fistula; Osteonecrosis; Povidone-Iodine; Tooth Extraction | 2011 |
Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.
Topics: Bone Density Conservation Agents; Cell Line; Cell Movement; Cell Proliferation; Cell Shape; Cell Survival; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Ibandronic Acid; Imidazoles; Jaw Diseases; Mesenchymal Stem Cells; Osteonecrosis; Time Factors; Zoledronic Acid | 2010 |
Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Cell Culture Techniques; Cell Differentiation; Clodronic Acid; Core Binding Factor Alpha 1 Subunit; Diphosphonates; Dose-Response Relationship, Drug; Gene Expression Regulation; Homeodomain Proteins; Humans; Ibandronic Acid; Imidazoles; MSX1 Transcription Factor; Osteoblasts; Osteocalcin; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transcription Factors; Zoledronic Acid | 2011 |
The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.
Topics: Apoptosis; Bone Density Conservation Agents; Cell Culture Techniques; Cell Line; Cell Movement; Cell Proliferation; Cell Survival; Clodronic Acid; Coloring Agents; Diphosphonates; Fluoresceins; Fluorescent Dyes; Humans; Ibandronic Acid; Imidazoles; In Situ Nick-End Labeling; Keratinocytes; Mouth Mucosa; Pamidronate; Tetrazolium Salts; Thiazoles; Zoledronic Acid | 2012 |
Bisphosphonates inhibit phosphorylation of signal transducer and activator of transcription 3 and expression of suppressor of cytokine signaling 3: implications for their effects on innate immune function and osteoclastogenesis.
Topics: Animals; Bone Density Conservation Agents; Cell Differentiation; Cell Survival; Cells, Cultured; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Ibandronic Acid; Immunity, Innate; Macrophages; Mice; Osteoclasts; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins | 2011 |
In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Chemotaxis; Clodronic Acid; Diphosphonates; Flow Cytometry; Granulocytes; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Neutrophils; Pamidronate; Phagocytosis; Respiratory Burst; Zoledronic Acid | 2015 |
High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis.
Topics: Alendronate; Apoptosis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Coloring Agents; Diphosphonates; Dose-Response Relationship, Drug; Flow Cytometry; G1 Phase; Humans; Ibandronic Acid; Necrosis; Osteoblasts; Pamidronate; Resting Phase, Cell Cycle; Spectrophotometry; Tetrazolium Salts; Thiazoles; Time Factors | 2015 |
The influence of geranylgeraniol on human oral keratinocytes after bisphosphonate treatment: An in vitro study.
Topics: Apoptosis; Bone Density Conservation Agents; Cell Culture Techniques; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Clodronic Acid; Diphosphonates; Diterpenes; Humans; Ibandronic Acid; Imidazoles; Keratinocytes; Mouth Mucosa; Pamidronate; Zoledronic Acid | 2015 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2016 |
Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro.
Topics: Administration, Oral; Alendronate; Apoptosis; Cell Movement; Cell Survival; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelial Cells; Fibroblasts; Humans; Ibandronic Acid; In Vitro Techniques; Infusions, Intravenous; Osteoblasts; Zoledronic Acid | 2018 |
Geranyl-geraniol addition affects potency of bisphosphonates-a comparison in vitro promising a therapeutic approach for bisphosphonate-associated osteonecrosis of the jaw and oral wound healing.
Topics: Acyclic Monoterpenes; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Endothelial Cells; Humans; Ibandronic Acid; Jaw Diseases; Mouth Diseases; Osteonecrosis; Wound Healing; Zoledronic Acid | 2022 |